ANKRD20A1

Across TCGA pan-cancer cohorts, ANKRD20A1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ANKRD20A1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher ANKRD20A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD20A1 expression acts as an unfavorable survival marker.

BRCA and LUAD are the cancer types where ANKRD20A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	DFS	Median	All	0.583	0.949	<.001	18	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ANKRD20A1–BRCA (DFS)

Open the BRCA breakdown →